CD68与ABHD5在胃癌组织中的表达及临床意义

doi:10.3760/cma.j.issn.1673-422X.2018.03.006

国际肿瘤学杂志 ›› 2018, Vol. 45 ›› Issue (3): 153-156.doi: 10.3760/cma.j.issn.1673-422X.2018.03.006

CD68与ABHD5在胃癌组织中的表达及临床意义

姚露岩，王子安

233004 蚌埠医学院第一附属医院肿瘤内科

收稿日期:2017-10-26 出版日期:2018-03-08 发布日期:2018-05-16
通讯作者: 王子安 E-mail:wangzian118@sina.com
基金资助:
安徽省高校自然科学研究重点项目（KJ2017A238）；蚌埠医学院研究生科研创新计划（Byycxz1614）

Expressions and clinical significances of CD68 and ABHD5 in gastric carcinoma

Yao Luyan, Wang Zian

Department of Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, China

Received:2017-10-26 Online:2018-03-08 Published:2018-05-16
Contact: Wang Zian E-mail:wangzian118@sina.com
Supported by:
Key Program of Natural Science Foundation of Anhui Higher Education Institutions of China (KJ2017A238); Postgraduate Research and Innovation Plan of Bengbu Medical College (Byycxz1614)

摘要/Abstract

摘要： 目的探讨CD68与含自水解酶域蛋白5（ABHD5）在胃癌组织中的表达及其与胃癌患者临床病理特征之间的关系以及两者的相关性。方法采用免疫组织化学法检测CD68及ABHD5蛋白在60例胃癌组织及30例癌旁正常组织中的表达情况，分析二者与胃癌患者临床病理特征的关系及二者的相关性。结果 CD68在胃癌组织和癌旁正常组织中的阳性表达率分别为65.00%、26.67%，差异有统计学意义（χ2=11.779，P=0.001）；ABHD5在胃癌组织和癌旁正常组织中的阳性表达率分别为60.00%、30.00%,差异有统计学意义（χ2 =7.200，P=0.007）。CD68的表达与临床TNM分期（χ2=7.959，P=0.005）、淋巴结转移（χ2=6.901，P=0.009）、浸润程度（χ2=5.833，P=0.016）相关，与病理分级（χ2=0.028，P=0.866）、性别（χ2=0.533，P=0.465）、年龄（χ2=0.060，P=0.807）无关；ABHD5的表达与病理分级（χ2=4.318，P=0.038）、TNM分期（χ2=4.051，P=0.044）、浸润程度（χ2=5.275，P=0.022）相关，与淋巴结转移（χ2=0.545，P=0.460）、性别（χ2=0.191，P=0.662）、年龄（χ2=1.358，P=0.244）无关。列联相关分析发现胃癌组织中CD68和ABHD5的表达呈正相关（c=0.328，P=0.010）。结论在胃癌组织中CD68及ABHD5表达较癌旁正常组织显著升高，二者表达与胃癌不同的临床病理特征相关，且CD68与ABHD5的表达呈正相关，联合检测胃癌组织中CD68和ABHD5的表达可能有助于对胃癌的转移、侵袭能力及预后进行评估。

关键词: 胃肿瘤, 含自水解酶域蛋白5, CD68

Abstract: Objective To evaluate the expressions of CD68 and alpha/beta hydrolase domaincontaining protein 5 (ABHD5) in gastric carcinoma and their interrelation, and the relationship with the clinicopathological features of gastric carcinoma. Methods The immunohistochemistry staining was used to determine the expressions of CD68 and ABHD5 in 60 cases of gastric carcinoma and 30 cases of adjacent normal tissues. The relationships between CD68, ABHD5 and clinicopathological features of gastric carcinoma, and the correlation of them were analyzed. Results The expressions of CD68 and ABHD5 in gastric carcinoma were significantly higher than those in adjacent normal tissues, and the positive expression rates were 65.00% vs. 26.67% (χ2=11.779, P=0.001) and 60.00% vs. 30.00% (χ2=7.200, P=0.007) respectively, with significant differences. The expression of CD68 was related to TNM stage (χ2=7.959, P=0.005), lymph node metastasis (χ2=6.901, P=0.009) and serosal invasion (χ2=5.833, P=0.016), but it was not associated with pathological grade (χ2=0.028, P=0.866), gender (χ2=0.533, P=0.465) and age (χ2=0.060, P=0.807). The expression of ABHD5 was related to pathological grade (χ2=4.318, P=0.038), TNM stage (χ2=4.051, P=0.044) and serosal invasion (χ2=5.275, P=0.022), but it was not associated with lymph node metastasis (χ2=0.545, P=0.460), gender (χ2=0.191, P=0.662) and age (χ2=1.358, P=0.244). Contingency correlation analysis showed that there was positive correlation between CD68 and ABHD5 in gastric cancer (c=0.328, P=0.010). Conclusion The expressions of CD68 and ABHD5 in gastric carcinoma are higher than those in adjacent normal tissues, which are correlated with the different clinicopathological features of gastric carcinoma. The expression of CD68 is positively correlated with the expression of ABHD5. The combined detection of CD68 and ABHD5 expressions in gastric carcinoma is helpful to evaluate the invasion, metastasis and prognosis of gastric carcinoma.

Key words: Stomach neoplasms, Alpha/beta hydrolase domaincontaining protein 5, CD68

姚露岩，王子安. CD68与ABHD5在胃癌组织中的表达及临床意义 [J]. 国际肿瘤学杂志, 2018, 45(3): 153-156.

Yao Luyan, Wang Zian. Expressions and clinical significances of CD68 and ABHD5 in gastric carcinoma[J]. Journal of International Oncology, 2018, 45(3): 153-156.

参考文献

［1］ Chanmee T, Ontong P, Konno K, et al. Tumorassociated macrophages as major players in the tumor microenvironment［J］. Cancers (Basel), 2014, 6(3): 1670-1690. DOI: 10.3390/cancers-6031670. ［2］ Noy R, Pollard JW. Tumorassociated macrophages: from mechanisms to therapy［J］. Immunity, 2014, 41(1): 4961. DOI: 10.1016/j.immuni.2014.06.010. ［3］ Biswas SK, Allavena P, Mantovani A. Tumorassociated macrophages: functional diversity, clinical significance, and open questions［J］. Semin Immunopathol, 2013, 35(5): 585-600. DOI: 10.1007/s0028101303677. ［4］ Holness CL, Simmons DL. Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins［J］. Blood, 1993, 81(6): 1607-1613. ［5］ Liang M, Mulholland DJ. Lipogenic metabolism: a viable target for prostate cancer treatment?［J］. Asian J Androl, 2014, 16(5): 661-663. DOI: 10.4103/1008-682x.132947. ［6］ Sanders MA, Zhang H, Mladenovic L, et al. Molecular basis of ABHD5 lipolysis activation［J］. Sci Rep, 2017, 7: 42589. DOI: 10.1038/srep42589. ［7］ Miao H, Ou J, Peng Y, et al. Macrophage ABHD5 promotes colorectal cancer growth by suppressing spermidine production by SRM［J］. Nat Commun, 2016, 7: 11716. DOI: 10.1038/ncomms11716. ［8］ Brown JM, Chung S, Das A, et al. CGI58 facilitates the mobilization of cytoplasmic triglyceride for lipoprotein secretion in hepatoma cells［J］. J Lipid Res, 2007, 48(10): 22952305. DOI: 10.1194/jlr.M700279-JLR200. ［9］ Miao H, Ou J, Ma Y, et al. Macrophage CGI58 deficiency activates ROSinflammasome pathway to promote insulin resistance in mice［J］. Cell Rep, 2014, 7(1): 223235. DOI: 10.1016/j.celrep.2014.02.047. ［10］ Huang CY, Fong YC, Lee CY, et al. CCL5 increases lung cancer migration via PI3K, Akt and NFkappaB pathways［J］. Biochem Pharmacol, 2009, 77(5): 794-803. DOI: 10.1016/j.bcp.2008.11.014. ［11］ Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation［J］. Cell, 2011, 144(5): 646674. DOI: 10.1016/j.cell.2011.02.013. ［12］ Zhang QW, Liu L, Gong CY, et al. Prognostic significance of tumorassociated macrophages in solid tumor: a metaanalysis of the literature［J］. PLoS One, 2012, 7(12): e50946. DOI: 10.1371/journal.pone.0050946. ［13］ Hashmi S, Wang Y, Suman DS, et al. Human cancer: is it linked to dysfunctional lipid metabolism?［J］. Biochim Biophys Acta, 2015, 1850(2): 352-364. DOI: 10.1016/j.bbagen.2014.11.004. ［14］ Santos CR, Schulze A. Lipid metabolism in cancer［J］. FEBS J, 2012, 279(15): 2610-2623. DOI: 10.1111/j.17424658.2012.08644.x.

[1]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[2]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[3]	解淑萍, 孙亚红, 汪超. 早期肿瘤标志物联合NLR、PLR预测胃癌免疫治疗疗效[J]. 国际肿瘤学杂志, 2024, 51(3): 157-165.
[4]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[5]	邵慧芳, 王学红, 芦永福. CST1在胃癌进展中的作用机制及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 489-492.
[6]	朱思雨, 王学红, 李文茜, 刘曙. 胃癌患者血清FABP1水平及其与幽门螺杆菌感染的关系[J]. 国际肿瘤学杂志, 2023, 50(6): 336-341.
[7]	杨娅, 王慧礼, 刘艳, 郭金凤, 王春霞, 吕敏, 山长平. GCSH基因在胃癌SNU-1细胞增殖和凋亡中的作用研究[J]. 国际肿瘤学杂志, 2023, 50(5): 257-262.
[8]	全祯豪, 徐飞鹏, 黄哲, 黄先进, 陈日红, 孙开裕, 胡旭, 林琳. 沉默lncRNA FTX通过miR-22-3p/NLRP3炎症体通路抑制胃癌细胞增殖[J]. 国际肿瘤学杂志, 2023, 50(4): 202-207.
[9]	姬薇, 关泉林, 陈雅蕊, 焦福智, 罗倩文. 血脂水平与胃癌的相关性[J]. 国际肿瘤学杂志, 2023, 50(3): 183-185.
[10]	范珊琳, 汪品秀, 孔飞, 周玉洁, 袁文臻. 胃癌新辅助化疗后肿瘤退缩分级预测因素的研究进展[J]. 国际肿瘤学杂志, 2023, 50(2): 112-116.
[11]	杨俊, 李荣, 曾建昌. 复方苦参注射液联合SOX方案治疗老年晚期胃癌的临床疗效[J]. 国际肿瘤学杂志, 2023, 50(2): 82-86.
[12]	邓莉莉, 段星宇, 李保中. HER2靶向药物及其联合治疗方案在胃及食管胃结合部腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(12): 751-757.
[13]	李佳宜, 王跃, 尚兰兰, 徐兴, 赵岩. 人工智能技术在胃癌诊断与治疗中的实践与展望[J]. 国际肿瘤学杂志, 2023, 50(11): 677-682.
[14]	于晓鹏, 冯青青, 赵文飞, 赵文文, 魏红梅. 靶向治疗联合免疫检查点抑制剂在HER2阳性进展期胃癌中的应用[J]. 国际肿瘤学杂志, 2023, 50(10): 631-635.
[15]	李立立, 安有志, 王艳军. 替雷利珠单抗治疗MSI-H局部晚期胃癌患者1例[J]. 国际肿瘤学杂志, 2022, 49(7): 444-446.

CD68与ABHD5在胃癌组织中的表达及临床意义

Expressions and clinical significances of CD68 and ABHD5 in gastric carcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价